Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. - sprookjes - yvandenbroek - TriplyDB

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

http://www.wikidata.org/entity/Q30583292

about

Novel myosin-based therapies for congenital cardiac and skeletal myopathies Signaling effectors underlying pathologic growth and remodeling of the heart Force generation by kinesin and myosin cytoskeletal motor proteins Integration of troponin I phosphorylation with cardiac regulatory networks Animal and in silico models for the study of sarcomeric cardiomyopathies Poorly understood aspects of striated muscle contraction Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor The myosin superfamily at a glance.A network-oriented perspective on cardiac calcium signaling Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology Targets for therapy in sarcomeric cardiomyopathies Small-molecule inhibitors of myosin proteins Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases Targeting the sarcomere to correct muscle function Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity β-Hydroxy-β-methylbutyrate reduces myonuclear apoptosis during recovery from hind limb suspension-induced muscle fiber atrophy in aged rats Potential new drug treatments for congestive heart failure.Multidimensional structure-function relationships in human β-cardiac myosin from population-scale genetic variation.Sarcomere length nanometry in rat neonatal cardiomyocytes expressed with α-actinin-AcGFP in Z discs.Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts.Harmonic force spectroscopy measures load-dependent kinetics of individual human β-cardiac myosin molecules Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.Influence of metabolic dysfunction on cardiac mechanics in decompensated hypertrophy and heart failure.Nitroxyl (HNO): A novel approach for the acute treatment of heart failure Analytical comparison of natural and pharmaceutical ventricular myosin activators Chaperone-enhanced purification of unconventional myosin 15, a molecular motor specialized for stereocilia protein trafficking Molecular motors: forty years of interdisciplinary research.Nemaline myopathy-related skeletal muscle α-actin (ACTA1) mutation, Asp286Gly, prevents proper strong myosin binding and triggers muscle weakness.Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels.Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy Myosin VI deafness mutation prevents the initiation of processive runs on actin Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.The sarcomeric protein nebulin: another multifunctional giant in charge of muscle strength optimization Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction.Myocyte contractility can be maintained by storing cells with the myosin ATPase inhibitor 2,3 butanedione monoxime.

P2860

Q26740449-876C362E-8128-4A5D-947C-7033750A6D41 Q26825154-1B103573-5BB7-4722-B152-D8C6D17D2E63 Q26827691-5D8A3921-D3CC-4072-9BFF-6F9E5E7FFBCD Q26852120-70176EC9-D0DB-4A9B-99F5-381AB79F6A39 Q26865437-53D48D1E-A849-433E-818F-E22B2159DD7F Q26866434-4BCBA317-7433-486A-8507-903F926F84C0 Q26996693-5056E412-7CCC-49D5-A838-EDEAE017CA27 Q27011868-EADAE227-9595-4F6A-AF43-66C7C70DBE0C Q27023389-11080789-1D6E-4BBD-83A6-249A914DCB44 Q27024879-AAED713E-9617-42ED-B6A1-952A050DC13A Q27027023-6F6D49C0-3007-46D3-A0EE-092A83FEE457 Q27027635-99D6DA42-9011-4051-94E4-027CCCBD3FF1 Q27320554-8E56F8BE-1333-4CC5-8481-7C97AD44A27E Q28085736-4FB06948-D6D7-4380-B557-18F326F322F4 Q28242602-99D0B0BA-2947-4B40-BB9B-810E593DD6DA Q28260224-C62E3E73-5BD9-4310-B51E-76619DA4049B Q28260629-FF6EA619-BCD6-43C5-93AF-794B815BC100 Q28304985-E7D54606-D2FC-421D-951D-827F57D78412 Q28391990-72269E0E-3383-433F-BF81-F9D206A63367 Q30251531-39409955-4D25-47CA-A9EA-8A46E67D7939 Q30388756-6C29880F-BBAF-4DA6-8580-C6E172A5F24B Q30575119-F7E67F33-B0D3-4B4C-BC79-8BAF3D41A3F2 Q30582828-C5CBA021-841B-436B-BD46-E223DD4D7C41 Q30660760-553BFA65-6DD3-4F32-9B5D-F9578C659318 Q33728779-7BE9536A-353F-4C1C-B3A6-044CB76237E2 Q33768442-FA430CF0-29A2-44E1-B1C6-F931609FA3DC Q33894414-D787C41F-A6AF-4739-B54A-05DB775618B2 Q33946688-6A69B7D7-CE79-4C24-B372-D84D2D5772AC Q34070160-1691AB76-1DAF-496B-84AC-15D408CD3880 Q34120199-4C78D746-5480-4FCD-9FF0-3D532257A715 Q34228870-F7C7DC6F-C94D-4313-B08B-7A4E83E02192 Q34430403-32546F27-E7FF-4496-9520-D722E0D7AD56 Q34549974-2825568A-E5A2-4A80-B8E2-7A1D1BD450B0 Q34755677-0B735F67-898B-4AEE-A41A-181CB35B7EDE Q35147071-7DA3872C-EA92-45F4-AA75-578B63BEE125 Q35212474-4707C275-635F-4874-AC15-21B0DC228670 Q35265639-4B5105C9-5F94-4B2C-95C1-E26AD9DE8C09 Q35778626-B2EAF070-BD84-40FF-846C-CCB98E727773 Q35844522-5E68201B-A5FD-402D-BEC2-91A8FF4636FA Q35908376-9397430F-94E5-4A86-BC21-7EB254FBFC42

P2860

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

http://www.wikidata.org/entity/Q30583292

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@ast

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@en

type

label

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@ast

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@en

prefLabel

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@ast

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@en

P1433

Q30583292-02A1DD10-A9FC-4BFE-AD27-2DFCB30462E7

P1476

Q30583292-9EBD42C5-F78B-4A00-8C14-FE3FB04C0B1F

P2093

Q30583292-04DB1438-E53E-4C01-87DC-5BAB4ABF21A4

Q30583292-0D8F0B61-1367-4A05-8AB3-E755BA251115

Q30583292-16D4FD27-CAF2-4065-ADBF-F69C55FA52FB

Q30583292-1BE906F5-5892-4178-B7E5-9D5128871339

Q30583292-36CF5CF6-D86A-48B0-9825-799CB007E273

Q30583292-4043BB8A-6F48-43CC-8689-91C1F473A80B

Q30583292-4DB3DA92-D494-40AE-B20D-4F3FE68910D2

Q30583292-60FD7692-65E7-424A-98C2-3CC46421FA4A

Q30583292-665A5E0C-007F-45D7-854F-FEE55B9A2B1D

Q30583292-67E46C78-F922-47D1-B411-7C0A01F0E7AE

P2860

Q30583292-0F5F7A31-9C1C-435A-A00E-34ED6FE4C37F

Q30583292-194284F5-4C8A-4941-BD1B-A6064B6F0953

Q30583292-1E7EFBBD-C38D-4789-8B5B-7039D203CE2E

Q30583292-2367F761-331E-4A80-B836-190D799B1D07

Q30583292-23E156E4-B301-4667-B53D-D9C5DB200195

Q30583292-306E9C6B-F7C9-4E56-97C0-B30E9B29F403

Q30583292-3241D492-30E7-435C-BFCD-AC40375CB4E6

Q30583292-36623971-172C-4285-98C5-AAA6360AF6FB

Q30583292-3CF767FD-7573-4223-AAE0-091145462404

Q30583292-3FB68302-05A6-4295-A55D-6053F75A23BD

P304

Q30583292-1EFCA5FE-7F27-4A5A-9E68-2070F1DA8B11

P31

Q30583292-7AFDF6C6-B196-48CC-A495-C68D30387536

P356

Q30583292-2D96240B-DAC9-474A-A2D7-38D02DB56FF7

P407

Q30583292-40BB1B27-0702-492A-BF31-912A3E79DCD4

P433

Q30583292-6C313306-8635-4D97-B42C-614DAB15C0FA

P478

Q30583292-E569D103-91AB-449F-94F3-A780AB048B55

P50

Q30583292-839B14A0-B671-46A8-8A3D-3BF8B39C828F

P577

Q30583292-810118E8-7767-4008-A265-D02D4CD01A6C

P5875

Q30583292-54DB3FBB-02A2-479D-8DC7-D958FFC37F93

P698

Q30583292-6EE6E3B7-23D8-4D93-AD20-5BBD657C5AA5

P921

Q30583292-468F1B70-923A-4EA6-9F10-9DCBFA53569A

Q30583292-AA18D004-0C08-458A-B123-5EF87BC4AE61

P932

Q30583292-58400FCB-A049-4737-B5AA-FECB2D0F7B44

P356

SCIENCE.1200113

P1433

P1476

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

@en

P2093

Alexander Muci

http://www.w3.org/2001/XMLSchema#string

Bradley P Morgan

http://www.w3.org/2001/XMLSchema#string

Congrong Niu

http://www.w3.org/2001/XMLSchema#string

Corey Valdez

http://www.w3.org/2001/XMLSchema#string

Daniel W Pierce

http://www.w3.org/2001/XMLSchema#string

David A Kass

http://www.w3.org/2001/XMLSchema#string

David J Morgans

http://www.w3.org/2001/XMLSchema#string

David Lenzi

http://www.w3.org/2001/XMLSchema#string

Erica Kraynack

http://www.w3.org/2001/XMLSchema#string

Fady I Malik

http://www.w3.org/2001/XMLSchema#string

P2860

Three-dimensional structure of myosin subfragment-1: a molecular motor

Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study)

Mechanism of adenosine triphosphate hydrolysis by actomyosin

Kinetic and equilibrium analysis of the myosin ATPase.

Clinical practice. Systolic heart failure.

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Alterations in left ventricular diastolic function in conscious dogs with pacing-induced heart failure.

Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide.

Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.

P304

1439-1443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1200113

http://www.w3.org/2001/XMLSchema#string

P407

P433

6023

http://www.w3.org/2001/XMLSchema#string

P478

331

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50420131

http://www.w3.org/2001/XMLSchema#string

P698

21415352

http://www.w3.org/2001/XMLSchema#string

P921

P932

4090309

http://www.w3.org/2001/XMLSchema#string